Dendreon appoints ex-J&J exec as its new CEO

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Dendreon appoints ex-J&J exec as its new CEO

Dendreon ($DNDN) has appointed W. Thomas Amick as its president and chief executive officer. Amick succeeds John Johnson, who previously announced his plans to step down from the position. Amick has held positions at Discovery Labs and Johnson & Johnson ($JNJ), where he served as vice president of the company's Ortho Biotech Oncology Franchise and helped launch Procrit. Release

Dendreon
W. Thomas Amick joined as the company's new CEO.


Polaris Partners
Amy Schulman joins Polaris after her stint at Pfizer.

Biotech

> Amy Schulman joined high-profile biotech investor Polaris as a venture partner. At Polaris, Schulman will help steer future investments, serve on the boards of some of the group's portfolio companies and take the top spot at one of its early-stage ventures. She is the only female partner currently at any of the Boston area's top VC firms. More

> Dyadic International appointed Thomas Dubinski as vice president and chief financial officer. Release

> Abide Therapeutics has appointed Nancy Thornberry to its board of directors. Release

> Gordon Sangster will join Codexis ($CDXS) as senior vice president and chief financial officer. Release

> Aegerion Pharmaceuticals ($AEGR) has appointed Craig Fraser as chief operating officer. Release

> MYOS ($MYOS) has appointed Douglas Weekes as chief commercial officer. Release

> Jeanine Swalec has joined Marathon Pharmaceuticals as its vice president of regulatory affairs. Release

> Intra-Cellular Therapies ($ITCI) has appointed Michael Halstead as senior vice president and general counsel. Release

> Dr. Thomas Wright has joined Enzo Biochem ($ENZ) as a consulting pathologist and medical adviser to the company's Women's Health Initiative. Release

> Envisia Therapeutics has appointed Adrienne Graves and Dr. Gary Phillips to its board as nonexecutive members. Release

> Inform Genomics named Carl De Moor as its chief technology officer. Release

> The American Diabetes Association appointed Suzanne Berry to be its interim CEO. Release

> Sarepta ($SRPT) Chairman William Goolsbee stepped down from the board of directors to be replaced by interim chairman John Hodgman. Release | Story

Pharma

> Astellas has appointed Moyra Knight as head of corporate and employee communications in the Americas region. Release

> Receptos ($RCPT) has announced the appointment of Mary Szela and Richard Heyman to its board of directors. Release

> Anne Whitaker is leaving her position as head of North America pharmaceutical operations at Sanofi ($SNY). Story | More

> Ranbaxy's Arno Gessner will head the Indian company's global quality division, and Alexander Gebauer will be its new head of global R&D. More

> ELC Group appointed Inna Demidova the head of its regulatory affairs for Russia and the Commonwealth of Independent States. Release

> ImaginAb appointed Dr. Roger Crystal as its vice president of business development. Release

Drug Delivery

> Egalet named Dr. Jeffrey Dayno as its chief medical officer. Release

> Arthur Tipton has been named president of the Controlled Release Society. Release

Pharma Manufacturing

> Rafarma Pharmaceuticals has appointed Bruno Horn as the new president and director of the company. Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.